

Edgar Filing: ROTH MICHAEL - Form SC 13G/A

ROTH MICHAEL  
Form SC 13G/A  
February 15, 2005

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES  
13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 2)\*

DOR BIOPHARMA, INC.

-----  
(Name of Issuer)

Common Stock, par value \$.001 per share

-----  
(Title of Class of Securities)

258094101

-----  
(CUSIP Number)

February 9, 2005

-----  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule  
is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities, and  
for any subsequent amendment containing information which would alter the  
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed  
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of  
1934 ("Act") or otherwise subject to the liabilities of that section of the Act  
but shall be subject to all other provisions of the Act (however, see the  
Notes).

SCHEDULE 13G

CUSIP NO. 258094101

Page 2 of 6

-----  
NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

1

Michael A. Roth and Brian J. Stark, as joint filers pursuant to  
Rule 13d-1(k)

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

Edgar Filing: ROTH MICHAEL - Form SC 13G/A

(b) [ ]

---

3	SEC USE ONLY
---	--------------

---

4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America

---

NUMBER OF	5	SOLE VOTING POWER
SHARES	0	

---

BENEFICIALLY	6	SHARED VOTING POWER
OWNED BY	3,817,046	(See Item 4)

---

EACH	7	SOLE DISPOSITIVE POWER
REPORTING	0	

---

PERSON	8	SHARED DISPOSITIVE POWER
WITH	3,817,046	(See Item 4)

---

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	3,817,046	(See Item 4)

---

10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
		[X]

---

11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
	7.6%	(See Item 4)

---

12	TYPE OF REPORTING PERSON
	IN

---

SCHEDULE 13G

CUSIP NO. 258094101

Page 3 of 6

Item 1(a). Name of Issuer:

DOR BioPharma, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

1691 Michigan Avenue  
Suite 435  
Miami, FL 33139

Items 2(a), (b) and (c). Name of Persons Filing, Address of Principal Business Office and Citizenship:

This Amendment No. 2 to Schedule 13G is being filed on behalf of Michael A. Roth and Brian J. Stark, as joint filers (collectively, the "Reporting Persons").

## Edgar Filing: ROTH MICHAEL - Form SC 13G/A

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Amendment No. 2 to Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Amendment No. 2 to Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of the Reporting Persons is 3600 South Lake Drive, St. Francis, WI 53235.

Item 2(d). Title of Class of Securities:  
  
Common Stock, par value \$.001 per share, of the Issuer (the "Common Stock")

Item 2(e). CUSIP Number:  
  
258094101

Item 3. Not applicable.

Item 4. Ownership.

(a) Amount beneficially owned:

3,817,046 shares of Common Stock\*

(b) Percent of class:

Based on 42,042,943 shares of Common Stock of the Issuer outstanding as of November 1, 2004 (as set forth in the Issuer's Form 10-QSB for the period ended September 30, 2004), and 8,396,100 shares of Common Stock of the Issuer issued in connection with the Issuer's private placement (as set forth in the Issuer's Form 8-K dated February 1, 2005),

### SCHEDULE 13G

CUSIP NO. 258094101

Page 4 of 6

the Reporting Persons hold approximately 7.6%\* of the issued and outstanding Common Stock of the Issuer.

(c) Number of shares to which such person has:

(i) Sole power to vote or direct the vote: 0

(ii) Shared power to vote or direct the vote: 3,817,046\*

(iii) Sole power to dispose or to direct the disposition of:  
0

(iv) Shared power to dispose of or direct the disposition of: 3,817,046\*

\*The Reporting Persons beneficially own an aggregate of 3,817,046 shares of Common Stock. The foregoing amount of Common Stock and percentage ownership represent the combined indirect holdings of Michael A. Roth and Brian J. Stark. The shares of Common Stock reported in this Amendment No. 2 to

## Edgar Filing: ROTH MICHAEL - Form SC 13G/A

Schedule 13G do not include certain shares of Common Stock issuable upon the exercise of warrants held by the Reporting Persons. Such warrants held by the Reporting Persons are subject to conversion caps that preclude the holder thereof from utilizing its exercise rights to the extent that it would beneficially own (determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) in excess of 4.999% and 9.999% of the Common Stock, giving effect to such exercise.

All of the foregoing represents an aggregate of 3,817,046 shares of Common Stock held directly by SF Capital Partners Ltd. ("SF Capital"). The Reporting Persons are the Managing Members of Stark Offshore Management, LLC ("Stark Offshore"), which acts as investment manager and has sole power to direct the management of SF Capital. Through Stark Offshore, the Reporting Persons possess voting and dispositive power over all of the foregoing shares. Therefore, for the purposes of Rule 13d-3 under the Exchange Act, the Reporting Persons may be deemed to be the beneficial owners of, but hereby disclaim such beneficial ownership of, the foregoing shares.

- Item 5. Ownership of Five Percent or Less of a Class.  
Not applicable.
- Item 6. Ownership of More than Five Percent on Behalf of Another Person.  
Not applicable.
- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.  
Not applicable.
- Item 8. Identification and Classification of Members of the Group.

### SCHEDULE 13G

CUSIP NO. 258094101

Page 5 of 6

Not applicable.

- Item 9. Notice of Dissolution of a Group.  
Not applicable.

- Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SCHEDULE 13G

Edgar Filing: ROTH MICHAEL - Form SC 13G/A

CUSIP NO. 258094101

Page 6 of 6

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 15, 2005

/s/ Michael A. Roth

-----  
Michael A. Roth

/s/ Brian J. Stark

-----  
Brian J. Stark

SCHEDULE 13G

CUSIP NO. 258094101

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Amendment No. 2 to Schedule 13G (including amendments thereto) with respect to 3,817,046 shares of Common Stock, of DOR BioPharma, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Amendment No. 2 to Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided, however, that no party is responsible for the completeness or accuracy of the information concerning any other party making the filing, unless such party knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement on February 15, 2005.

/s/ Michael A. Roth

-----  
Michael A. Roth

/s/ Brian J. Stark

-----  
Brian J. Stark